Rocket Pharmaceuticals appoints Piratip Pratumsuwan to Board; Yalamanchi resigns

ROCKET PHARMACEUTICALS, INC.

Naveen Yalamanchi resigned from Board effective Jan 25, 2025; no disagreement.
Piratip Pratumsuwan appointed to Board effective Jan 27, 2025.
Pratumsuwan is Managing Director, Research Analyst at RTW Investments, specializing in gene therapy.
Received option grants: $360k (3-year monthly vest) and $155k (1-year cliff vest).
Age 33; M.A. in Biotechnology from Columbia, B.S. in Biochemistry from McGill.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Piratip Pratumsuwan

Director

RCKT · ROCKET PHARMACEUTICALS, INC.

Effective: 2025-01-27
Filed: January 28, 2025, 6:59 PM ET

On January 25, 2025, the Board, upon the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Piratip Pratumsuwan to the Board, effective January 27, 2025.

Departed

Naveen Yalamanchi

Director

RCKT · ROCKET PHARMACEUTICALS, INC.

Effective: 2025-01-25
Filed: January 28, 2025, 6:59 PM ET

On January 25, 2025, Naveen Yalamanchi resigned from the Board of Directors (the “Board”) of Rocket Pharmaceuticals, Inc. (the “Company”), effectively immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Piratip Pratumsuwan was appointed as Director at ROCKET PHARMACEUTICALS, INC..

Action: appointed
Role: Director

Exact text from the filing

On January 25, 2025, the Board, upon the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Piratip Pratumsuwan to the Board, effective January 27, 2025.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Naveen Yalamanchi resigned as Director at ROCKET PHARMACEUTICALS, INC..

Action: resigned
Role: Director

Exact text from the filing

On January 25, 2025, Naveen Yalamanchi resigned from the Board of Directors (the “Board”) of Rocket Pharmaceuticals, Inc. (the “Company”), effectively immediately.

View on SEC.gov

ROCKET PHARMACEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0001140361-25-002103

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.